Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bone marrow mononuclear cells (BM-MNCs) are an investigational cell therapy developed by Fuzhou General Hospital for the treatment of type 2 diabetes mellitus. The therapy involves harvesting a patient's own bone marrow, isolating the mononuclear cell fraction (which includes hematopoietic stem cells, mesenchymal stem cells, and progenitor cells), and infusing them directly into the pancreas via intra-arterial pancreatic infusion. This approach aims to promote the regeneration of insulin-producing β-cells and improve the local microenvironment through the release of paracrine factors and cytokines. In clinical studies, this cell therapy has been evaluated both as a monotherapy and in combination with hyperbaric oxygen therapy (HOT) to enhance cell survival and functional recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow mononuclear cells (900th Hospital of Joint Logistics Support Force of PLA).